Viagenpumatucel-L
Viagenpumatucel-L (pronounced: vee-ah-gen-poo-mah-too-sel-el) is an investigational immunotherapy drug that is being studied for the treatment of non-small cell lung cancer (NSCLC).
Etymology
The name "Viagenpumatucel-L" is derived from the method of its production. "Via" refers to the method of delivery, "gen" refers to the genetic modification involved in its production, "puma" refers to the PUMA protein, a key component of the drug, and "tucel" is a common suffix used in the naming of biologic drugs.
Mechanism of Action
Viagenpumatucel-L is designed to stimulate the body's immune system to recognize and attack cancer cells. It is made by genetically modifying a patient's own cancer cells to produce an immune system-stimulating protein called PUMA. The modified cells are then reintroduced into the patient's body, where they are recognized as foreign by the immune system and targeted for destruction. This process is intended to train the immune system to recognize and attack other cancer cells in the body.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Viagenpumatucel-L in patients with NSCLC. These trials have shown promising results, with some patients experiencing significant improvements in survival and quality of life. However, further research is needed to confirm these findings and determine the optimal dosing and administration schedule for this drug.
Related Terms
External links
- Medical encyclopedia article on Viagenpumatucel-L
- Wikipedia's article - Viagenpumatucel-L
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski